文献速递骨肿瘤关节外科

股骨压缩式骨整合假体至少10年随访的长期手术结局

What Are the Long-term Surgical Outcomes of Compressive Endoprosthetic Osseointegration of the Femur with a Minimum 10-year Follow-up Period?
PubMed 文献 · Clin Orthop Relat Res · 2022-01-01

单中心回顾性研究纳入25例股骨原发骨肉瘤患者接受压缩式骨整合假体重建,20例完成至少10年随访。10年因无菌性松动、假体周围骨折或机械断裂的再手术风险为12%(95%CI 0%至26%),并发症均发生于术后29个月内,无晚期翻修。影像学显示14例皮质肥厚、6例维持原生皮质轮廓,无皮质萎缩。

要点

  • 10年再手术风险为12%(95%CI 0%至26%),并发症均在术后29个月内出现。
  • 无患者发生晚期无菌性松动、假体周围骨折或机械断裂。
  • 影像学无晚期皮质萎缩或应力遮挡,支持界面长期稳定。

核心结论

  • 压缩式骨整合假体在至少10年随访中无因假体周围骨折、无菌性松动或假体断裂导致的晚期翻修。
  • 宿主-假体界面无晚期皮质萎缩或应力遮挡证据,支持该固定方式的长期稳定性。

研究设计与样本

  • 单中心回顾性研究,2002年至2010年纳入110例股骨近端或远端原发骨肉瘤患者,其中25例接受压缩式骨整合假体。
  • 25例中5例在10年随访前死亡(2例局部复发截肢,3例带假体死亡),最终20例完成分析。
  • 中位年龄18岁(范围7至50岁),25例中13例为男性;中位随访144个月,20例存活者随访至少10年(121至230个月)。
  • 主要终点为因假体周围骨折、无菌性松动或机械断裂导致的再手术和假体取出,采用竞争风险分析。

主要发现

  • 3例出现 spindle 骨折或松动,其余17例维持压缩装置至末次随访。
  • 10年因无菌性松动、假体周围骨折或机械断裂的再手术风险为12%(95%CI 0%至26%)。
  • 上述并发症均发生于术后29个月内,此后无患者出现假体松动或机械故障。
  • 影像学评估显示14例骨-假体界面皮质肥厚,6例维持原生皮质轮廓,无患者出现界面皮质萎缩或变窄。

临床怎么用

  • 对于符合条件的年轻股骨骨肉瘤患者,压缩式骨整合假体可提供至少10年的稳定固定。
  • 术后早期(约29个月内)需重点监测假体周围骨折、无菌性松动或机械断裂。
  • 长期随访中影像学若见皮质肥厚或维持原生轮廓,无需担心晚期皮质萎缩。

局限性

  • 单中心回顾性设计,样本量小(最终分析20例),证据等级为Level IV。
  • 研究仅纳入50岁及以下、无既往股骨放疗、无影响骨愈合代谢病、无转移且预期寿命大于6个月的患者,外推受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endoprosthetic reconstruction after oncologic resection of bone tumors requires stable fixation between the prosthesis and residual host bone. Compressive osseointegration has been developed as an alternative to traditional stemmed implants to address the challenges and complications of achieving this fixation. Sufficient time has now passed from the advent of compressive implants to allow for an assessment of the intermediate-term and long-term results of this form of fixation. QUESTIONS/PURPOSES: At a minimum follow-up of 10 years after implantation of a compressive osseointegration device for oncologic reconstruction: (1) What is the risk of periprosthetic fracture, aseptic loosening, or implant breakage resulting in revision surgery for endoprosthesis removal? (2) What is the long-term cortical response at the host-endoprosthesis interface as visualized on plain radiographs? METHODS: A single-center, retrospective study was performed between 2002 and 2010, in which 110 patients with primary bone sarcoma of the proximal or distal femur were considered for oncologic resection and reconstruction. Patients were considered for a compressive osseointegration endoprosthesis if they were 50 years of age or younger, had not previously received femoral radiation, had no metabolic disease impairing bone healing, were not diagnosed with metastatic disease, and had life expectancy greater than six months. Of the 110 patients, 25 were treated with a compressive osseointegration implant of the proximal or distal femur, and 85 patients were treated with conventional stemmed implants or amputation because of older age, advanced disease, metabolic comorbidities, inability to tolerate a nonweightbearing postoperative period, or in the case of rotationplasty, patient preference. All patients who received this device during the period of study were considered eligible for inclusion in this review. The median (range) age was 18 years (7 to 50), and 13 of 25 patients were men. Five patients died of disease before the minimum follow-up duration of 10 years; two underwent amputation due to local recurrence and three died with the implant in situ, leaving 20 patients for complete analysis. Median follow-up was 144 months, and all 20 surviving patients had a minimum follow-up of 10 years (121 to 230 months). The primary endpoint was reoperation and implant removal for periprosthetic fracture, aseptic loosening, or mechanical breakage of any component of the compressive device in the endoprosthesis. In final analysis, death was considered a competing event to revision surgery, and cumulative incidence was reported after competing-event analysis. A secondary aim was radiographic evaluation of the host-implant interface to assess the long-term cortical response to compressive osseointegration. RESULTS: Spindle fracture or loosening was noted in three patients, and the remaining 17 patients maintained the compression device until the final follow-up. The risk of reoperation for aseptic loosening, periprosthetic fracture, or mechanical breakage of the implant using a competing risks estimator was 12% at 10 years (95% CI 0% to 26%). These complications occurred within 29 months of the index surgery; no patients had implant loosening or mechanical breakdown after this initial period. On radiographic assessment, 14 patients demonstrated cortical hypertrophy of the bone-implant interface, six patients had maintenance of the native cortical contour, and no patients had cortical atrophy or narrowing at the implant interface.Conclusion Long-term follow-up in patients with compressive osseointegrative endoprosthetic devices demonstrated no late revisions because of periprosthetic fracture, aseptic loosening, or implant breakage in this cohort with a minimum 10-year follow-up. There was no evidence of late-onset cortical atrophy or stress shielding at the host-implant interface. This study supports the long-term stability of the interface between host bone and the endoprosthesis in compressive osseointegration devices. LEVEL OF EVIDENCE: Level IV, therapeutic study.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Groundland J, Brown JM, Monument M, et al. What Are the Long-term Surgical Outcomes of Compressive Endoprosthetic Osseointegration of the Femur with a Minimum 10-year Follow-up Period? Clin Orthop Relat Res. 2022. PMID: 34559734. doi:10.1097/CORR.0000000000001979

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。